Pardo, O.E., Wellbrock, C., Khanzada, U.K., Aubert, M., Arozarena, Imanol, Davidson, S., Bowen, F., Parker, P.J., Filonenko, V.V., Gout, I.T., Sebire, N., Marais, R., Downward, J. and Seckl, M.J. (2006) FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. Embo Journal, 25 (13). pp. 3078-3088. ISSN 0261-4189Metadata only available from this repository.
Patients with small cell lung cancer (SCLC) die because of chemoresistance. Fibroblast growth factor-2 (FGF-2) increases the expression of antiapoptotic proteins, XIAP and Bcl-X(L), and triggers chemoresistance in SCLC cells. Here we show that these effects are mediated through the formation of a specific multiprotein complex comprising B-Raf, PKCepsilon and S6K2. S6K1, Raf-1 and other PKC isoforms do not form similar complexes. RNAi-mediated downregulation of B-Raf, PKCepsilon or S6K2 abolishes FGF-2-mediated survival. In contrast, overexpression of PKCepsilon increases XIAP and Bcl-X(L) levels and chemoresistance in SCLC cells. In a tetracycline-inducible system, increased S6K2 kinase activity triggers upregulation of XIAP, Bcl-X(L) and prosurvival effects. However, increased S6K1 kinase activity has no such effect. Thus, S6K2 but not S6K1 mediates prosurvival/chemoresistance signalling.
|Subjects:||R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)|
|Schools:||School of Applied Sciences|
|Depositing User:||Imanol Arozarena Arozarena|
|Date Deposited:||03 Mar 2015 15:21|
|Last Modified:||03 Mar 2015 15:21|
Downloads per month over past year
Repository Staff Only: item control page